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Abstract The objective of the present study is to charac-
terize genitourinary tumors (GU) metastatic to the head and
neck and to determine long-term prognoses. Using a retro-
spective chart review of 734 patients treated between Janu-
ary 1995 and May 2005 with an ICD-9 code pertaining to a
metastatic head and neck cancer, we found 37 patients with
primary GU tumors. There were 24 cases of prostate can-
cer, 10 cases of renal cell carcinoma, and 4 cases of transi-
tional cell carcinoma. Sixteen of 24 patients (67%) with
prostate cancer had a cranial metastasis while 6 of 9 (67%)
patients with renal cell carcinoma had cerebral metastasis.
We concluded that prolonged survival is possible in pros-
tate cancer patients treated aggressively with radiation and
chemotherapy, indicating that early detection and aggres-
sive screening are important in these patients.
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Introduction
Head and neck cancer is the Wfth most common cancer
worldwide [1]. In the United States, head and neck cancers
account for 3.3% of all malignancies [2]. The cervical
lymph nodes are a common site of metastasis for cancers
originating in the upper aerodigestive tract. Rarely, cancers
originating from sites other than the head and neck can
metastasize to the cervical lymph node chain. However,
genitourinary tract neoplasms make up a signiWcant propor-
tion of these cancers and should be considered in the diVer-
ential diagnosis of neoplastic lesions of the head and neck
[3]. A study reported and identiWed 31 (3.7%) of 845 geni-
tourinary tumors metastasized to the head and neck and 21
tumors (2.5%) metastasized to the cervical lymph nodes
[3]. Ferlito et al. [4] reported a series of genitourinary
tumors and found this group to be the third most frequent
tumor site to metastasize to the supraclavicular fossa.
Epithelioid tumors in the head and neck are common and
include both primary and metastatic lesions [5]. Metastatic
lesions, clinical factors, tumor location, and ancillary
immunohistochemical studies must be taken into consider-
ation to help the clinician and the pathologist to determine
the site of origin. A group of unusual, but important, pri-
mary tumors that can metastasize to the head and neck are
genitourinary tumors consisting of carcinoma of the pros-
tate (CAP), renal cell carcinoma (RCC), which is also
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known as clear cell carcinoma, and bladder cancer, of
which the most common type by far is transitional cell car-
cinoma (TCC) [6].
Prostate carcinoma is the second most common cause of
cancer death among American men [7]. It has been estab-
lished that more than 30% of men over the age of 50 will
develop this devastating disease [8]. Established risk fac-
tors include age, ethnicity and family history [9]. Although
most of the metastatic prostate cancers will arise in the
axial skeleton or the pelvic lymph nodes, it has been
reported to spread to the axillary and cervical lymph nodes
of the head and neck region [3, 4]. A retrospective study
identiWed 26 cases of metastatic prostatic carcinoma
involving the supraclavicular lymph nodes, which were the
most common site of invasion [4]. One study reported 26
cases in which the most common primaries with metastasis
to the sphenoid sinus were prostate adenocarcinoma, with
an incidence of 20% [10]. Ferlito et al. [4] reported 5 of 21
cases (24%) were normal for serum acid phosphatase, 7 of
20 cases (35%) had no evidence of metastases to bones, 8
of 19 (42%) cases had normal rectal examination and 19 of
26 cases presented with physical Wndings of urinary
obstructive symptoms or enlarged lymph nodes despite no
history of prostate cancer. This shows that the diagnosis of
prostate cancer cannot rely only on clinical or serological
examination. Rather it also depends highly on the combina-
tion of cytological or histological features with immuno-
staining using prostate-speciWc antigen and prostatic acid
phosphatase.
Renal cell carcinoma accounts for 3% of all malignan-
cies and can metastasize to any location in the body, and its
propensity to metastasize to unusual sites has been well
documented. Approximately, 30% of patients with RCC
present with metastatic disease, 25% with locally advanced
renal carcinoma, and 45% with localized disease [11]. It is
the third most frequent neoplasm to metastasize to the head
and neck region preceded only by breast and lung cancer
[12]. In spite of being reported infrequently, head and neck
region metastases may be linked to RCC in up to 8–15% of
cases [11]. SpeciWcally, regions in the head and neck
include the paranasal sinuses, larynx, jaws, temporal bones,
thyroid gland, and parotid glands [13, 14]. RCC metastases
to the nose and paranasal sinuses are most commonly
aVected followed by the tongue [15].
In a minority of patients, the classical presentation of
RCC manifests itself in the classical triad of pain, hematu-
ria, and Xank mass. Unfortunately, head and neck metasta-
sis from RCC is usually a manifestation of widespread
disease and it is often indicative of advanced disease. RCC
may remain clinically occult for most of its course. The
expected 5- and 10-year survival rates for these patients are
5–30 and 0–5%, respectively [11]. Approximately, 75% of
patients with RCC metastasize most commonly to the
lungs, 20% to bone, 18% to liver, 36% to soft tissue and 8%
to central nervous system [16].
Bladder neoplasm accounts for 2–6% of all tumors, with
bladder cancer becoming the fourth most common cancer
occurring in the United States, with an increase in inci-
dence after 65 years [17]. Bladder cancer is the second
most prevalent cancer for men and the tenth most prevalent
cancer for women [17]. Bladder carcinoma metastases are
commonly found in bone (75%), followed by lymph nodes
(26%) and lung (20%) [4]. Supraclavicular lymph node
metastases are rare and indicate widespread disease with
poor prognosis. Metastases of the head and neck regions
are also uncommon and their most frequent sites are the
brain, supraclavicular nodes, neck nodes and the skull [3].
Hessan et al. [3] reported and identiWed 3 of 207 cases
(1.4%) for cervical lymph nodes. Very few cases of TCC
metastasize to the oral cavity, including one reported case
in the maxilla [18] and seven reports identiWed in the man-
dible [19]. Only four cases have been described in the oral
soft tissues one in the tongue [20] and one in the subman-
dibular gland [21].
Metastatic tumors to the head and neck are extremely
rare. Therefore, the literature is based largely on sporadic
case reports. Possible routes of metastasis to the head and
neck include arterial, venous and lymphatic circulations.
These include paravertebral venous plexus (Batson’s) or
through the thoracic lymphatic duct. Overall, correct diag-
nosis is important, as these patients may achieve remission
and prolonged survival with chemotherapy, irradiation and/
or hormonal therapy.
Materials and methods
The Systematized Nomenclature of Medicine (SNOMED)
Wles of the Greater Los Angeles VA Medical System
(GLAVAMS) Department of Pathology were searched for
cases of metastatic CAP, RCC, and TCC. SNOMED is a
newer version of the widely used Decentralized Hospital
Computer Program (DHCP) which is a way of classifying
medical terms based on topography and morphology.
Multiple searches were performed through VISTA system
which is a Massachusetts General Hospital Utility Multi-
Programming System (MUMPS)-based hospital database.
Medical records of 14,756 patients with genitourinary
cancers being treated or referred to the GLAVAMS from
January 1995 to May 2005 were pulled out. Among those,
734 patients who had an ICD-9 code pertaining to a meta-
static head and neck cancer were selected and their medi-
cal records were thoroughly studied. All relevant slides
were examined, and clinical information was obtained
from the referring physician’s patient charts (Tables 1, 2
and 3).Eur Arch Otorhinolaryngol (2010) 267:273–279 275
123
Table 1 Characteristics of prostate cancer (CAP) cases metastatic to the head and neck
Case # Site of mets Gleason score Presentation of metastasis Age at CAP Survival (years) Year at mets
1 Virchow 9 Swelling 52 1 1
2 Skull (diVuse) 4+X Pain in cranium 54 5 5
3 Temporal lobe 7 Incontinence LE weakness 69 10 8
4 Dura matter 5 Diplopia, blindness 74 9a 1
5 Dura matter 7 Confusion 56 10a 7
6 Virchow 7 Neck mass 79 3 1
7 Orbit skull base 9 Blindness 85 3 2
8 Temporal lobe 8 HA 59 5 3
9 Virchow 8 Neck mass 80 15 14
10 Virchow 6 Neck mass 57 13 9
11 Midbrain, cavernous sinus NA Right hand weakness 75 4 3
12 Brain (diVuse) 7 Disequilibrium 62 9 1
13 Virchow 9 Neck mass 57 7 7
14 Orbit frontal lobe NA Proptosis, ptosis redness 70 7 6
15 Brain (diVuse) 7 Confusion, seizure 63 2 2
16 Temporal lobe 7 Left side weakness 52 5 4
17 Parotid 9 VII cranial nerve palsy 62 1 1
18 Clivus NA XII cranial nerve palsy 59 5 5
19 Brain (diVuse) NA NA 58 10 10
20 Sphenoid 7 Left side hyperreXexia, anisocoria 71 10 10
21 Orbit dura matter NA Blindness and headache 63 3 2
22 Virchow NA Neck mass 75 4 2
23 Virchow 8 Neck mass 59 2 1
24 Skull (fronto temporal) NA Confusion 75 4 4
Case # PSA * serum Hormone response Treatment
1 5,500 Ref [1] Goserelin, bicalutamide
2 >1,000 Ref Goserelin, Xutamide, TRFP
3 4 Treatment late in the course of disease Fronto temporal craniotomy, XRT, goserelin/Xutamide, TURP
4 2522 Sen [2] Luperolide, ketoconazole, XRT
5 938 Sen Goserelin, bicalutimide, Xutamide, ketoconazole, TURP
6 279 Sen Goserelin, bicalutimide,
7 126 Sen XRT, goserelin, Xutamide
8 13 Ref Prostatectomy, goserelin, Xutamide, ketoconazole, estramustine, VP 16, XRT
9 7869 Ref Prostatectomy, bicalutamide,
10 5.2 Ref Prostatectomy, goserelin, bicalutimide, docetaxel
11 NA Ref Hormonal TX, XRT, vinblastine, estramustine
12 284 Sen Orchiectomy, hormonal TX, XRT
13 14 Ref XRT, goserelin, bicalutimide, ketoconazole, Xutamide
14 1165 Ref XRT, leperamide, bicalutamide, vinblastine, estramustine
15 51 Ref Goserelin, Xutamide
16 >100 Ref Craniotomy, TURP, orchiectomy, chemotherapy
17 NA Ref XRT, estramustine
18 66 Ref XRT, total prostatectomy, bilateral orchiectomy
19 214 NA Luperamide
20 46 Ref XRT, hormonal therapy
21 13 Ref XRT, hormonal therapy
22 4 Ref XRT, estramustin/taxotere carboplatin,
23 9 Ref Goserelin, bicalutamide, XRT
24 NA Ref Luperamide, bicalutimide276 Eur Arch Otorhinolaryngol (2010) 267:273–279
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Results
We describe 37 cases of metastatic CAP, RCC, and TCC to
the head and neck, consisting of 24 cases of CAP, 9 cases
of RCC, and 4 cases of TCC.
Carcinoma of the prostate
Among 24 patients with CAP 16 patients (67) had a cranial
metastasis. The location of the metastases consisted of
brain, cerebellum, dura, skull, scalp or a combination of
Table 2 Metastatic RCC of head and neck region and their characteristics
a Still alive
b Cancer presented with mets
c Initial diagnosis and work up at another institution, further records not available
Case # Mets Present Age at Dx Year at mets Survival (years) Tob.
1 Frontal lobe HA, LUE Numbness, weakness 24 4 17a ¡
2 Cerebellum HAb, N/V, blurry vision 51 0 5 +
3 Frontal lobe, mandible, scalp Cystic lesions in the scalpb 55 0 1 +
4 Frontal lobe Frontal HA, memory loss 53 1 3 ¡
5 Frontal, occipital lobes, cerebellum Dizzinessb, dysarthria, dysphagia 58 0 1 +
6 Parotid Parotid mass 67 1 14a +
7E y e c 55 11 14 +
8 Tongue Tongue cyst 27 0 1 ¡
9B r a i n H A 6 2 0 < 1 +
Case # Pathology Other mets Para-neoplastic 
syndromes
Treatments
1 Poorly diVerentiated carcinoma, 
staining for GFAP
Lung None Right frontal lobe craniotomy, 
nephrectomy, immune therapy, 
chemotherapy
2 Poorly diVerentiated (grade III), Bone marrow, liver None Nephrectomy, posterior fossa craniotomy, 
hepatic wedge resection, chemotherapy, XRT
3 c Adrenal, lungs, 
liver, skin
Hypercalcemia IL-2, IFN a, XRT
4 Clear cell type (grade II) None Hypercalcemia Nephrectomy, craniotomy
5 Clear cell (not graded) Lungs Hypercalcemia XRT
6 Moderately well diVerentiated 
(grade II)
Colon Polycythemia, 
hypercalcemia
Nephrectomy, colectomy
7 c Bone None Nephrectomy, XRT, eye enucleation
8 Grade III Spine, lung, liver Hypercalcemia XRT, nephrectomy
9 Diagnosed by FNA Bone, lungs Hypercalcemia XRT
Table 3 Transitional cell carcinoma (TCC) of the bladder with metastasis to the brain
Case # Site of mets Presentation Pathology Age at TCC Survival (years)
1 Brain (diVuse) Headache NA 58 2
2 Cerebellum Gate disturbance, 
jerky movements, headache
High grade-poorly 
diVerentiated
73 1
3 Sphenoid, cavernous sinus Ptosis, headache Papillary TCC, grade II 62 1
4 Cerebellum Headache High grade TCC 55 7
Case # Tobacco Other sites Co-morbidities Treatment
1 30PY Spinal cord High triglyceride XRT, spinal fusion, transurethral resection
2 60PY Liver, lung Prostate cancer Sub-occipital craniotomy, transurethral resection
35 0 P Y L i v e r D V T X R T
4 None None DVT Transurethral resection, chemotherapy, sub-occipital craniotomyEur Arch Otorhinolaryngol (2010) 267:273–279 277
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these. Seven patients (29%) had a brain metastasis. Five
cases (21%) had a bony skull metastasis. Three patients
(13%) had a metastasis to the meninges and in two cases
(11%) there was a pure dural metastasis. One of the cases
with a temporal lobe metastasis also had a tumor on the
scalp (not in Table). In three out of eight patients (37%)
with brain metastasis, the tumor was found in the temporal
lobe. One patient (13%) had a pure frontal lobe metastasis.
Interestingly, both patients with frontal lobe metastases also
had orbit and dural involvement. In both cases of dural
involvement, the involvement was conWned to the frontal
dura matter. The base of the skull was a favorite site of
involvement in patients with metastasis to the skull. There
were two cases with spread to the clivus and base of the
skull and one case of sphenoid bone involvement.
Seven patients (29%) had a tumor in their supraclavicu-
lar lymph nodes (Virchow’s lymph node). Three cases
(13%) had involvement of the orbit and presented with eye
pain, proptosis, or loss of vision, while in one case the
tumor cells had spread to the optic nerve. One case (4%)
had involvement of the parotid gland.
The mean Gleason score was 7.5 (range 5–9). However,
after reviewing the patient histories in the CPRS system
and studying their Wles in the medical records, eight cases
did not have a complete Gleason’s grade. Those patients
were diagnosed before January 1995 with the primary diag-
nosis made in another institution.
The average age of onset for the prostate cancer was
62.8 (range 52–85) years and the average years of survival
after the diagnosis of CAP was 6.1 years (range 1–15). Two
of the 24 patients (8%) are alive. The mean survival after
the diagnosis of the head and neck metastases was less than
4.5 years. Bone involvement was almost a universal Wnding
among the cases. Only two cases (11%) had only soft tissue
involvement in the head and neck.
The average PSA at the time of diagnosis was 54.2,
which was followed by a drop of the values after the initial
treatment. This was followed by a rise before the presenta-
tion of the metastases and the average PSA at that time was
958; however, three patients had missing data. All of the
cases except for one case were refractory to hormonal ther-
apy. Craniotomy was performed in two patients with a soli-
tary temporal lobe tumor.
Two patients had no history of CAP at the time of biopsy
of the head and neck metastasis, and 12 patients (50%) had
other widespread metastatic disease at the time of presenta-
tion of the metastases. Histologically, most of the tumors
had epithelioid cells with prominent nucleoli and cribri-
form, solid, or inWltrating single cell growth patterns. PSA
and PSAP immunohistochemical stains were positive in all
cases except case 14 which had a positive PSA staining and
negative PSAP staining. Two of 12 patients with known
follow-up are alive after radiation or hormonal therapy.
Renal cell carcinoma
Among nine patients with RCC with metastases to the head
and neck, six patients (67%) had metastases to the brain.
There was one metastasis each to the parotid gland, the eye,
and the tongue (11%). One patient among the group had
metastases to both the brain and mandible. No metastases
to the supraclavicular lymph node were reported. All but
one of the patients with brain metastases had frontal lobe
involvement; the remaining metastasis was to the cerebel-
lum. One patient had concomitant involvement of the
occipital and frontal lobes and cerebellum. The mean age of
diagnosis was 50.2 (range 24–67). In Wve (56%) patients
RCC presented with the head involvement. Two patients
developed metastases after 1 year of RCC diagnosis and
one patient developed eye metastasis 11 years after the ini-
tial diagnosis of the RCC. Two-thirds of the patients were
tobacco users with the mean age at the presentation of their
cancer of 58 versus 34.6 years in patients without history of
tobacco use. Six patients had hypercalcemia at some point
during the course of their disease. Three patients with sin-
gle brain metastasis went through craniotomy and resection
of the tumor. The mean survival was 8.6 years after the cra-
niotomy versus 6.2 years in three patients who were not
treated with craniotomy.
Transitional cell carcinoma
In this study, we had four patients with TCC who devel-
oped cranial metastases during the course of their disease.
Two patients had metastases to the cerebellum, and in both
the tumor was resected. All but one of the patients with
TCC had over 30 pack year history of tobacco use. One
patient with metastasis to the cerebellum lived for 7 years
following craniotomy. One patient had metastases to the
bony and vascular structures of the skull without brain
parenchyma involvement. None of the patients in this
group had involvement of the neck or facial structures.
Discussion
Surgery and radiation therapy, recently augmented by
induction chemotherapy, can be eVective in the treatment of
head and neck carcinomas. These results demonstrate a fair
prognosis with possible prolonged survival with metastatic
CAP to the head and neck after appropriate diagnosis and
subsequent hormone and radiation therapy. Given this sur-
vival advantage with treatment, it is critical to consider the
diagnosis of metastatic CAP when evaluating a metastatic
malignant epithelioid tumor in the head and neck of an eld-
erly man. In this study, temporal lobe was a favorite site for
metastasis among patients with intracranial spread of the278 Eur Arch Otorhinolaryngol (2010) 267:273–279
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tumor. This Wnding along with the fact that 50% of the
cases had a single tumor allows for the possibility of poten-
tially improving the patients’ prognosis with craniotomy
and resection of the tumor. Correct diagnosis is crucial, as
these patients may achieve remission and prolonged sur-
vival with irradiation and hormonal therapy.
Our results show a clear tendency of RCC to metastasize
to the frontal lobe. The second favorite location for this
cancer to metastasize was to the cerebellum. It was shown
that patients with solitary RCC metastasis to the brain
greatly beneWt from aggressive intervention and tumor
resection. This Wnding further emphasizes the importance
of early detection and management of these metastases in
this patient population with special attention to any newly
developed headache, and motor or sensory deWcit in this
group. Including a thorough neurologic examination in
each follow-up visit for patients with RCC might have a
positive inXuence on their life expectancy. The Wnding of
lower age of onset in RCC patients without a history of
tobacco use might be explained by a genetic propensity for
developing cancer in this group. All the patients in the RCC
group who had age of onset of over 50 years also had a his-
tory of tobacco use. This Wnding was striking in that it
could pose tobacco use as a major risk factor for RCC
patients to develop head and neck metastases. This Wnding
was also true in patients with TCC in whom 75% with brain
metastases had a strong history of tobacco use.
In general, the presence of metastases in the patient pop-
ulation with genitourinary cancers heralds a poor prognosis
making the discovery of these cancers in the head and neck
an oncologically important Wnding. The negative impact of
head and neck metastases was especially shown to be true
in prostate cancer patients whereas under certain circum-
stances patients with metastatic RCC to the head and neck
might be good candidates for further intervention and have
better outcomes.
Partial or total nephrectomy is the therapeutic approach
usually used in metastatic disease to improve the quality of
life or symptomatic relief [22]. Treatment of RCC metasta-
sis in the head and neck is directed mainly towards pallia-
tion. Excision is usually performed to control pain and to
manage any potential complications from a space occupy-
ing mass in the head and neck region, including the brain.
Radiotherapy can improve symptomatic relief or quality of
life for perhaps a few months. Little data exist regarding the
use of systemic therapy in the setting of RCC metastasis to
the head and neck. Still, most of the patients die within
1 year after detection of head and neck metastasis; there-
fore, therapeutic decisions should maximize comfort and
minimize morbidity considering the poor long-term prog-
nosis at this stage of the disease.
Lymph node metastasis has long been known to be a
poor prognostic factor in kidney cancer and is an important
prognostic factor even in the presence of distant hematoge-
nous metastasis. Lymph node involvement has a poor prog-
nosis with a 5-year survival rate of 5–30%, which happens
to be similar to systemic metastases. In spite of studies sug-
gesting beneWt from extended lymph node dissection, there
appears to be inconclusive data from controlled, random-
ized studies to support any surgical advantage [23].
Whether a patient will beneWt lymph node dissection
involving an early or isolated involvement of lymph nodes
has yet to be investigated in controlled, randomized clinical
studies.
Chemotherapy combined with interferon has shown
to provide palliative beneWt in some patients with RCC.
One prospective trial compared and showed that in
properly selected patients with metastatic disease,
immunologic therapy following radical nephrectomy
may improve time to progression. Nephrectomy com-
bined with systemic cytokine gave a greater survival
advantage over the group treated with only immunother-
apy [24]. Nevertheless, immunologic agents are limited
and often prematurely stopped due to their systemic side
eVects and toxicity.
Newer agents targeting the VEGF pathway such as bev-
acizumab and sorafenib have shown to improve progres-
sion-free survival in metastatic RCC [25, 26]. Early phase
trials with bevacizumab and sorafenib may provide hope
for cytokine-refractory patients with metastatic RCC.
Genitourinary tumors have been shown to metastasize to
the head and neck region in rare instances. Therefore, the
work-up of a new head or neck lesion in light of a history of
genitourinary tumors should include metastases as part of
the diVerential diagnosis. If a diagnosis of genitourinary
metastases is established, additional therapeutic options,
including immunotherapy, surgery, and chemotherapy
should be discussed with the patient despite the poor prog-
nosis.
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